Interviews
Adriana Kertzer, Founder of Jewish Healing Society – Interview Series

Key PointsAdriana Kertzer founded the Jewish Healing Society to support Jews in psychedelic…
View more
- Adriana Kertzer founded the Jewish Healing Society to support Jews in psychedelic medicine and science.
- Psychedelic law is uniquely unsettled because rules are being written while lawyers practice.
- Kertzer sold Plant Medicine Law Group's assets to Emerge Law Group after MDMA therapy failed FDA approval.
While major cannabis reforms at the federal level are now possible in the coming years, it’s worth noting that the second half of the 2020s could see significant psychedelic reforms implemented as well. Various local municipalities have already enacted decriminalization ordinances for psilocybin mushrooms, and Colorado has even established a medical program for psilocybin. As reforms are discussed at both the state and federal levels simultaneously, having experienced lawyers behind these efforts will be incredibly beneficial to the success of upcoming legislation. With legislation, of course, comes normalization, and increased research into natural psychedelics has people from all walks of life interested in their potential. Whether driven by internal reasons or external factors, the interest surrounding natural psychedelics is certainly growing.
For a more in-depth look into crucial upcoming pieces of psychedelic reform legislation to watch—as well as how people are developing an appreciation for natural psychedelics, particularly within the Jewish community—mycannabis.com spoke with Adriana Kertzer, Founder of the Jewish Healing Society.
What topics did you study at Brown University?
Brown University was the most expensive Hebrew school I could have attended! I grew up in a secular Zionist family in Brazil with no Jewish education, and before college I took a gap year that brought me to Israel, India, Algeria, Spain, France, England, Greece and Italy. I actually went to Israel during my gap year because my grandfather offered to pay for that part of the gap year (I had never been). There I volunteered on Julis army base with Sar El in 1998, cleaning tanks and washing cucumbers at a moment when the country feared that Saddam Hussein would retaliate against it if Iraq were attacked, just as he had in 1991. The base was on alert, so we learned how to use gas masks and received instructions about the injections we would administer if biological weapons were used, and although my parents begged me to return to Brazil, I refused to leave because I deeply felt my connection to Israel and what it meant to be a part of a tribe as a result of my experiences in the country. It was also during that gap year that an antisemitic experience in Italy sparked my desire to learn more about my Jewish heritage, so when I arrived at Brown I chose a double major in Judaic Studies (focused on feminist theory and Latin American Jewish migration) and International Relations (centered on the social, political and economic relationship between the United States and Brazil). As a Jew from São Paulo, I felt most alive in the classes where those two worlds overlapped, such as Prophets in the Tropics: Jewish Latin American Literature. Looking back, though, the course that planted the deepest seed was one on the history of Kabbalah and messianism, because it introduced me to the ways Jews have always longed for transformation, and I return to those themes constantly in my work at the intersection of Jewish culture and altered states.
What inspired you to attend law school, and why did you choose Georgetown Law? What fields of law did you initially study?
I went to law school with three passions: women’s human rights, international law, and the restitution of art stolen during World War II. Restitution was where my two Brown majors met, because it combined Jewish history with international relations and treated law as the tool that could actually return what had been taken. Georgetown made sense both for its strength in international law and for its location in Washington, DC, which put me close to where policy gets made. I was a Global Law Scholar there, and my studies ranged from international law and human rights to corporate and securities law. It was that corporate training that led me to start my career on the Latin American capital markets team at Simpson Thacher & Bartlett, where I spent four years working in Portuguese and English to help Brazilian companies go public and offer their shares to American investors.
What were the most rewarding and exciting aspects of your roles with prestigious museums such as The Guggenheim Museum and Museum of Arts and Design?
Both roles let me sit where law, culture and people meet. As Acting Assistant General Counsel at the Guggenheim, I worked on the Tino Sehgal exhibition, a live artwork in which interpreters of all ages, including children, held conversations with visitors as they walked up the rotunda. Because the piece was made entirely of human interaction, sorting out the child labor questions behind it became one of the most creative legal problems I have ever worked on.
At the Museum of Arts and Design, I joined Lowery Stokes Sims as a curatorial assistant and digital strategist on New Territories, the first U.S. museum group show of contemporary Latin American design. Lowery first hired me as a consultant in March 2013, when I led a design research trip to São Paulo and Rio for her and coordinated curatorial meetings in Mexico City. I then spent January 2014 to January 2015 on the museum’s curatorial team, where I managed the exhibition’s logistics, led its digital strategy, oversaw production of the catalogue and revised the museum’s loan, guest curator and image rights contracts. The show later traveled to The Albuquerque Museum and to Museo Amparo in Puebla, Mexico. Some of the objects Lowery chose came from my book Favelization, published by Cooper Hewitt, Smithsonian Design Museum, so watching that research come to life in a New York museum was a dream, and I contributed an essay to the exhibition catalogue as well. I also wanted the visiting designers to be able to present their work to a New York audience, so I organized a mini conference during opening week, where thirteen of the show’s artists and designers presented in a pecha kucha to a packed room on November 5, 2014. A month later I organized and moderated a panel on digital fabrication in Latin America with Guto Requena and Sebastian Errazuriz. Together, those events gave me my first taste of what I still love most, which is bringing the right people into the same room.
My museum years also included a role as Curatorial Fellow at the Cooper Hewitt and a teaching assistant at Parsons, where I earned my M.A. in the History of Decorative Arts and Design and where Favelization began as an essay for a class called Theorizing Luxury. The book eventually took me to speak in Hong Kong, Mexico City, Richmond and Puebla, and it has since been taught in courses at Parsons, Birkbeck and the Universidade de Lisboa. Later I worked for the Obama Administration as Senior Advisor to the Senior Deputy Chairman of the National Endowment for the Arts, where I ran a monthly lecture series called Art Futures and organized and moderated the Making in the Arts panel at the 2015 National Maker Faire in Washington.
While working with Chestnut Hill Advisory Partners, what types of clients did you primarily work with? How did your law degree help in that role, given the industries you worked with?
I founded Chestnut Hill Advisory Partners in 2010 as a creative consultancy for complex cultural and real estate projects, and the clients were wonderfully varied. For example, I drafted the winning proposal to the NYC Parks Department to redesign and manage bike rental concessions in city parks, a request that covered rental stations in Central Park, Riverside Park, West Harlem Piers Park, East River Park and Highbridge Park. I led the drafting while the architects at Architecture in Formation created the renovation plans and renderings. I also led a prospective hotel project in Kingston, New York for Grupo Habita, a Mexican hotel group, and advised a music-focused coworking and studio developer in Toronto. For Magic City, a street art exhibition produced by a German concert and exhibition company that opened in Dresden in October 2016 with Carlo McCormick as curator, I negotiated contracts, drafted the artist, loan and video license agreements, and acted as the liaison between the producers in Germany and the curatorial team in the US. That same year, Mad Men property master Ellen Freund hired me to help install an exhibit about the show for Modernism Week in Palm Springs. Houses became part of the work as well: I turned the renovation of Olivebridge Cottage, my own second home in the Catskills, into an experiment in digital storytelling and the sharing economy, and in 2017 an investor hired me to get Grace Cottage, a waterfront house on Long Island, Maine, renovated and rental ready. In Harlem, I co-hosted Harlem Paladar, a series of sold-out pop-up dinners in my living room with chef Carolina Santos-Neves, and in 2018 I spoke on the Music Urbanism panel at SXSW. Through all of it, my law degree was what tied the work together, because whether the project was a hotel, a bike concession or an art show, someone had to read the fine print, anticipate risk and turn a creative vision into documents people could sign. I still use Chestnut Hill today to advise philanthropists who want to invest in Jewish psychedelic infrastructure.
When exactly did you decide to found Plant Medicine Law Group, and when did you see a necessity for a law firm that specialized in psychedelic-related matters? What were some notable cases that you oversaw with that firm?
I co-founded Plant Medicine Law Group with Hadas Alterman and Serena Wu in 2020 as the first law firm focused on psychedelic infrastructure. Back then we could see a psychedelic industry forming in real time, and the companies, nonprofits, practitioners and researchers building it needed lawyers who understood both the science and the culture. For PMLG, psychedelic infrastructure meant the healthcare and Schedule I legal questions behind new mental health therapies, and we served clients in New York, Oregon, Colorado, and California. Over the next few years I grew the firm from a solo practice into a four person team, while the firm was featured in the media and at industry events and produced courses for legal professionals entering the psychedelic industry. In 2024, after the FDA declined to approve MDMA-assisted therapy, state legalization efforts stalled, and a rise in antisemitism affected the business, I sold the firm’s assets to Emerge Law Group (which has since been sold to Vicente). I later served as General Counsel of Fluence, which trains clinicians in psychedelic therapy. Our work at PMLG spanned the whole ecosystem, from organizations building retreat and clinical models to the nonprofits and researchers pushing the field forward. During those same years I also launched Faith+Delics, which brought Jews, Christians and Muslims together for a year to study psychedelics in their communities, and I served on the boards of Shine Collective and of Doctors for Drug Policy Reform, where I led the rebrand and the inclusion of psychedelics.
From your experience, how is being a psychedelic lawyer unlike practicing any other field of law?
In most areas of law the rules are settled and your job is to apply them, whereas in psychedelics the rules are being written while you work. A single substance can be Schedule I under federal law, decriminalized in a city, regulated in a state program and legal in a clinic across the border, all at the same time. On top of that, clients often arrive after a profound personal experience, which means you are advising on compliance and on someone’s life mission in the same meeting. And because the field touches healing, religion and culture, you have to bring cultural competence to the table along with legal skill, which is a big part of why I started thinking about what Jewish clients and patients specifically need. More importantly, you have an active underground that affects or intersects with the legal world in ways you have to monitor and understand.
When was the Jewish Healing Society founded? What were some of the factors that influenced the creation of the organization?
I launched the Jewish Healing Society in February 2025, but its roots go back to 2016, when I started JewWhoTokes to build community at the intersection of Jewish culture and altered states. It began as an Instagram account profiling Jewish thought leaders, creatives and people who work in the cannabis and psychedelic industries. Around the same time I was writing Rebranding Pot, a series of articles about the changing aesthetics of the cannabis industry and the design strategies cannapreneurs were using to shed the plant’s stigma. That research brought me to Brown University’s Leaders in Cannabis panel in 2017, and the following year I began co-hosting happy hours for people in the cannabis industry with Masha Kupets Navarre of Plastic Palmtree.
After October 7, 2023, that community became a lifeline for Jews facing antisemitism in the cannabis and psychedelic industries. We started weekly pre-Shabbat Zoom calls that were equal parts learning and kvetching, with guests who included rabbis, dispensary owners, doctors, lawyers, filmmakers and philanthropists, and we gathered in person as well. Our Bagel Bash brought more than 200 Jews together in Las Vegas during MJBizCon in November 2023, and that December we held a High + Mighty Hanukkah Bash at the House of Cannabis in New York.
By 2025 it was clear that the cannabis and psychedelic conversations each needed a home of their own, so the JewWhoTokes Instagram became Jews in Weed, and I created the Jewish Healing Society to focus on psychedelics and mental health. Today I run the Jewish Healing Society, which is committed to fostering a supportive environment for Jews in psychedelic medicine and science, ensuring that Jews can learn about, advance research on and obtain safe access to the benefits of psychedelics without discrimination and fear.
The need for this work is real. According to the Jewish Journeys study from Shefa and Emory University, 30% of respondents have served as a guide for someone else, which tells me that Jews are not only seeking psychedelic healing but also holding space for one another, and those guides deserve education and support.
What have been some of the most notable and memorable events that Jewish Healing Society has hosted? Why were those events so important towards greater understanding of psychedelics?
Our Remembering October 7 support and prayer groups, co-led with Dr. Erica Zelfand and Liat Rayson, gave Jews in the psychedelic world a place to grieve together at a time when many of their professional spaces felt unsafe, and they showed that a psychedelic community can hold trauma with care rather than politics.
In November 2025, I also returned to Georgetown University to deliver a guest lecture titled “Psychedelic Law + Jewish Psychedelia” in Psychedelics, Law & Religious Culture, a course co-taught by Jessica Roda. In it, I drew on my experience running Plant Medicine Law Group to explain what culturally competent care for Jews looks like in both therapeutic and underground psychedelic settings. Events like these matter because psychedelic media tends to avoid Israel and Jewish life while Jewish institutions tend to avoid psychedelics, and JHS lives in the gap between them.
On October 7, 2026, I moderated a conversation in Austin about the first clinical trial of ibogaine in Israel, a hospital-based phase 1 safety trial for severe, treatment-resistant PTSD led by Hadassah and Tel Aviv Sourasky Medical Center with MAPS Israel. Bringing an Israeli researcher directly to American supporters turned what had been a distant headline into a relationship.
On the legal front, what are some of the most important pieces of legislation surrounding psychedelic reform or court cases being discussed on Capitol Hill right now?
This has been a remarkable year for psychedelic policy, and for ibogaine in particular. On April 18, President Trump signed an executive order to speed up the review of psychedelic treatments, including ibogaine, and Americans for Ibogaine (the nonprofit created by Bryan Hubbard and Rick Perry) was instrumental in bringing that order about. I played a behind-the-scenes role in that organization from the start, since I convened the dinner that led to its creation and then helped form it, and today I do similar work as an advisor to Israelis for Ibogaine, which supports the first clinical trial of ibogaine in Israel.
Congress is now working to make parts of the executive order permanent, and among the bills in play is the bipartisan IBOGAINE Act (H.R. 9559) from Reps. Morgan Luttrell, Lou Correa, Jack Bergman and Michael McCaul, which would push for a decision on moving ibogaine from Schedule I to Schedule II and set up rescheduling for other Schedule I substances that complete Phase 3 trials.
The news keeps coming. On November 12, 2026, the day after Veterans Day, Health Secretary Robert F. Kennedy Jr. announced that ARPA-H is backing the Mark Cuban Cost Plus Drug Company to develop ibogaine for PTSD in collaboration with the VA, with a commitment of up to $4.9 million over five years that is tied to research milestones. Cuban’s company will build the regulatory and manufacturing foundation for a US-made ibogaine hydrochloride product, and while his entrepreneurship is well known, his Jewish identity also played a significant role in his life’s trajectory.
The announcement also named Beond, an ibogaine clinic operator in Mexico co-founded by Talia Eisenberg, which will provide clinical data on safety, dosing, efficacy and durability drawn from more than 3,000 patients. Talia’s grandmother survived Auschwitz, a history she shared when she testified at the Kentucky Opioid Abatement Advisory Commission’s public hearing on ibogaine in September 2023 (I introduced Talia to Bryan Hubbard early on in his work with ibogaine). I’m watching everything closely, especially because ibogaine is a medicine I am personally reverent of and Israeli hospitals hope to one day run ibogaine research of their own, and I hope these efforts can learn from each other.
Thank you for joining us, Adriana! For more information on Jewish Healing Society, please visit its website.












